| Serial Number | 98513412 |
| Word Mark | ZURPAVY |
| Filing Date | Monday, April 22, 2024 |
| Status | 686 - PUBLISHED FOR OPPOSITION |
| Status Date | Tuesday, March 18, 2025 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, March 18, 2025 |
| Goods and Services | Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressant preparations, pharmaceutical antibodies for medical use, and immunotherapy preparations for the treatment of cancer; cytokine inhibitory drugs being pharmaceutical preparations for the treatment of cancer; anticoagulants; Pharmaceutical preparations for human use that modulate the immune system for the treatment of immune-system related diseases and disorders; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy for the treatment of cancer; Pharmaceutical and biological preparations for human use, namely, stem cells for medical use; Pharmaceutical preparations for human use for the treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies for medical use; Pharmaceutical preparations for human use for the treatment of neuropsychiatric disorders; therapeutic radiopharmaceutical preparations for human use for the treatment of cancer and solid tumors; diagnostic radiopharmaceutical preparations for human use; diagnostic preparations for human use for medical purposes; radiopharmaceutical preparations for human use in the nature of imaging and detection agents for diagnosing and monitoring cancer; biological preparations for human use in the nature of radio-isotope markers for therapeutic or diagnostic use; Pharmaceutical preparations for human use for the treatment of cystic fibrosis |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Monday, April 22, 2024 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Celgene Corporation |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | Princeton, NJ 08543 |
| Party Name | Celgene Corporation |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Princeton, NJ 08543 |
| Event Date | Event Description |
| Monday, April 22, 2024 | NEW APPLICATION ENTERED |
| Thursday, September 12, 2024 | NON-FINAL ACTION E-MAILED |
| Thursday, September 12, 2024 | ASSIGNED TO EXAMINER |
| Thursday, October 10, 2024 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Thursday, September 12, 2024 | NON-FINAL ACTION WRITTEN |
| Thursday, September 12, 2024 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Friday, January 3, 2025 | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND |
| Friday, January 3, 2025 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE |
| Tuesday, January 7, 2025 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Tuesday, January 7, 2025 | PETITION TO REVIVE-GRANTED |
| Tuesday, January 7, 2025 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Tuesday, January 7, 2025 | TEAS PETITION TO REVIVE RECEIVED |
| Tuesday, January 7, 2025 | NOTICE OF REVIVAL - E-MAILED |
| Tuesday, January 7, 2025 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Thursday, February 20, 2025 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, March 12, 2025 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, March 18, 2025 | PUBLISHED FOR OPPOSITION |
| Tuesday, March 18, 2025 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |